Chronic constipation: From syndrome to diagnosis and effective therapy

Chronic constipation is a generally recognized medical and social problem and occupies a leading place in the number of requests for outpatient medical care among patients with a gastroenterological profile in many countries of the world. The persistent trend in recent years towards an increase in global prevalence regardless of gender, age and socioeconomic status emphasizes the relevance of studying and systematizing data on the causes of chronic constipation and optimal approaches to diagnosis in order to improve the effectiveness of treatment of patients. A particular difficulty in managing patients with chronic constipation is identifying the etiological factor due to the presence of a wide range of possible causes. This often increases the time of diagnosis and complicates the timely initiation of rational therapy. According to etiology, chronic constipation is classified as primary (functional) – an independent disease in the absence of organic or metabolic disorders and secondary – as a symptom of another pathology or associated with a known factor. In clinical practice, the majority of cases are patients with primary chronic constipation, namely, with functional constipation and irritable bowel syndrome with a predominance of constipation. The diagnostic algorithm for chronic constipation should be aimed at assessing “alarm symptoms”, excluding organic pathology and other secondary causes. This involves a thorough collection of complaints, anamnesis of the disease and life, physical examination and the appointment of the necessary laboratory and instrumental examination methods, the scope of which is determined individually. The basis of therapy for a patient with primary chronic constipation is lifestyle modification. In the absence of a positive effect from non-drug methods, it is advisable to prescribe laxatives – osmotic action as first-line therapy, stimulating or agonists of 5HT4 receptors in case of insufficient response to the former. One of the stimulant laxatives that has shown its effectiveness and a reliable safety profile in the treatment of patients with primary chronic constipation is sodium picosulfate.

1. Bharucha AE, Lacy BE. Mechanisms, Evaluation, and Management of Chronic Constipation. Gastroenterology. 2020;158(5):1232–1249.e3. https://doi.org/10.1053/j.gastro.2019.12.034.

2. Barberio B, Judge C, Savarino EV, Ford AC. Global prevalence of functional constipation according to the Rome criteria: a systematic review and metaanalysis. Lancet Gastroenterol Hepatol. 2021;6(8):638–648. https://doi.org/10.1016/S2468-1253(21)00111-4.

3. Peery AF, Crockett SD, Murphy CC, Lund JL, Dellon ES, Williams JL et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology. 2019;156:254–272.e11. https://doi.org/10.1053/j.gastro.2018.08.063.

4. Salari N, Ghasemianrad M, Ammari-Allahyari M, Rasoulpoor S, Shohaimi S, Mohammadi M. Global prevalence of constipation in older adults: a systematic review and meta-analysis. Wien Klin Wochenschr. 2023;135(15-16):389–398. https://doi.org/10.1007/s00508-023-02156-w.

5. Маев ИВ, Кучерявый ЮА, Черёмушкин СВ, Андреев ДН. Хронический запор с позиций современной медицины: пособие для врачей. М.: Прима Принт; 2020. 40 с. Режим доступа: https://zacofalk.ru/files/662293e265b915e8879248a89c4c64181640635717.pdf.

6. Dimidi E, Cox C, Grant R, Scott SM, Whelan K. Perceptions of Constipation Among the General Public and People With Constipation Differ Strikingly From Those of General and Specialist Doctors and the Rome IV Criteria. Am J Gastroenterol. 2019;114(7):1116–1129. https://doi.org/10.14309/ajg.0000000000000267.

7. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol. 1997;32(9):920–924. https://doi.org/10.3109/00365529709011203.

8. Sayuk GS, Yu QT, Shy C. Management of Constipation in Hospitalized Patients. J Clin Med. 2023;12(19):6148. https://doi.org/10.3390/jcm12196148.

9. Drossman DA, Hasler WL. Rome IV-Functional GI Disorders: Disorders of Gut-Brain Interaction. Gastroenterology. 2016;150(6):1257–1261. https://doi.org/10.1053/j.gastro.2016.03.035.

10. Sharma A, Rao SSC, Kearns K, Orleck KD, Waldman SA. Review article: diagnosis, management and patient perspectives of the spectrum of constipation disorders. Aliment Pharmacol Ther. 2021;53(12):1250–1267. https://doi.org/10.1111/apt.16369.

11. Milosavljevic T, Popovic DD, Mijac DD, Milovanovic T, Krstic S, Krstic MN. Chronic Constipation: Gastroenterohepatologist’s Approach. Dig Dis. 2022;40(2):175–180. https://doi.org/10.1159/000516976.

12. Jani B, Marsicano E. Constipation: Evaluation and Management. Mo Med. 2018;115(3):236–240. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC6140151/.

13. Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J et al. Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2021;160(1):99–114.e3. https://doi.org/10.1053/j.gastro.2020.04.014.

14. Siah KT, Wong RK, Whitehead WE. Chronic Constipation and Constipation-Predominant IBS: Separate and Distinct Disorders or a Spectrum of Disease? Gastroenterol Hepatol (N Y). 2016;12(3):171–178. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC4872845/.

15. Lacy BE, Mearin F, Chang L, Chey WD, Lembo AJ, Simren M et al. Bowel disorders. Gastroenterology. 2016;150(6):1393–1407.e5. https://doi.org/10.1053/j.gastro.2016.02.031.

16. Wong MYW, Hebbard G, Gibson PR, Burgell RE. Chronic constipation and abdominal pain: Independent or closely interrelated symptoms? J Gastroenterol Hepatol. 2020;35(8):1294–1301. https://doi.org/10.1111/jgh.14970.

17. Alavi K, Thorsen AJ, Fang SH, Burgess PL, Trevisani G, Lightner AL et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Evaluation and Management of Chronic Constipation. Dis Colon Rectum. 2024;67(10):1244–1257. https://doi.org/10.1097/DCR.0000000000003430.

18. Bunni J, Laugharne MJ. Pathophysiological basis, clinical assessment, investigation and management of patients with obstruction defecation syndrome. Langenbecks Arch Surg. 2023;408(1):75. https://doi.org/10.1007/s00423-023-02755-1.

19. Алешин ДВ, Ачкасов СИ, Баранская ЕК, Ивашкин ВТ, Куликова НД, Лапина ТЛ и др. Запор: клинические рекомендации. М.; 2024. 48 с. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/274_3.

20. Hojo M, Shibuya T, Nagahara A. Management of Chronic Constipation: A Comprehensive Review. Intern Med. 2025;64(1):7–15. https://doi.org/10.2169/internalmedicine.2867-23.

21. Akyüz F, Çelebi A, Doğan İ, Erzin Y, Kav T, Soytürk M et al. Functional Bowel Disorder Management in Routine Practice with Tips for Hot Topics: Expert Opinion Review. Turk J Gastroenterol. 2024;35(6):423–439. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC11232060/.

22. Schiller LR. Nutrients and constipation: Cause or cure? Pract Gastroenetrol. 2008;32(4):43–46, 48–49. Available at: https://med.virginia.edu/ginutrition/wp-content/uploads/sites/199/2015/11/SchillerArticle-April-08.pdf.

23. Deiteren A, Camilleri M, Burton D, McKinzie S, Rao A, Zinsmeister AR. Effect of meal ingestion on ileocolonic and colonic transit in health and irritable bowel syndrome. Dig Dis Sci. 2010;55(2):384–391. https://doi.org/10.1007/s10620-009-1041-8.

24. Stephen AM, Champ MM, Cloran SJ, Fleith M, van Lieshout L, Mejborn H, Burley VJ. Dietary fibre in Europe: current state of knowledge on definitions, sources, recommendations, intakes and relationships to health. Nutr Res Rev. 2017;30(2):149–190. https://doi.org/10.1017/S095442241700004X.

25. Bulsiewicz WJ. The Importance of Dietary Fiber for Metabolic Health. Am J Lifestyle Med. 2023;17(5):639–648. https://doi.org/10.1177/15598276231167778.

26. Bellini M, Tonarelli S, Barracca F, Rettura F, Pancetti A, Ceccarelli L et al. Chronic Constipation: Is a Nutritional Approach Reasonable? Nutrients. 2021;13(10):3386. https://doi.org/10.3390/nu13103386.

27. Black CJ, Yuan Y, Selinger CP, Camilleri M, Quigley EMM, Moayyedi P, Ford AC. Efficacy of soluble fibre, antispasmodic drugs, and gut-brain neuromodulators in irritable bowel syndrome: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(2):117–131. https://doi.org/10.1016/S2468-1253(19)30324-3.

28. van der Schoot A, Drysdale C, Whelan K, Dimidi E. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. Am J Clin Nutr. 2022;116(4):953–969. https://doi.org/10.1093/ajcn/nqac184.

29. Fathallah N, Bouchard D, de Parades V. Diet and lifestyle rules in chronic constipation in adults: From fantasy to reality… Presse Med. 2017;46(1):23–30. (In French) https://doi.org/10.1016/j.lpm.2016.03.019.

30. Eady SL, Wallace AJ, Butts CA, Hedderley D, Drummond L, Ansell J, Gearry RB. The effect of ‘Zesy002’ kiwifruit (Actinidia chinensis var. chinensis) on gut health function: a randomised cross-over clinical trial. J Nutr Sci. 2019;8:e18. https://doi.org/10.1017/jns.2019.14.

31. Chey SW, Chey WD, Jackson K, Eswaran S. Exploratory Comparative Effectiveness Trial of Green Kiwifruit, Psyllium, or Prunes in US Patients With Chronic Constipation. Am J Gastroenterol. 2021;116(6):1304–1312. https://doi.org/10.14309/ajg.0000000000001149.

32. Bayer SB, Gearry RB, Drummond LN. Putative mechanisms of kiwifruit on maintenance of normal gastrointestinal function. Crit Rev Food Sci Nutr. 2018;58(14):2432–2452. https://doi.org/10.1080/10408398.2017.1327841.

33. Richardson DP, Ansell J, Drummond LN. The nutritional and health attributes of kiwifruit: a review. Eur J Nutr. 2018;57(8):2659–2676. https://doi.org/10.1007/s00394-018-1627-z.

34. Jayasinghe M, Karunanayake V, Mohtashim A, Caldera D, Mendis P, Prathiraja O et al. The Role of Diet in the Management of Irritable Bowel Syndrome: A Comprehensive Review. Cureus. 2024;16(2):e54244. https://doi.org/10.7759/cureus.54244.

35. Galica AN, Galica R, Dumitrașcu DL. Diet, fibers, and probiotics for irritable bowel syndrome. J Med Life. 2022;15(2):174–179. https://doi.org/10.25122/jml-2022-0028.

36. Serra J, Pohl D, Azpiroz F, Chiarioni G, Ducrotté P, Gourcerol G et al. European society of neurogastroenterology and motility guidelines on functional constipation in adults. Neurogastroenterol Motil. 2020;32(2):e13762. https://doi.org/10.1111/nmo.13762.

37. Severo JS, Silva ACAD, Santos BLBD, Reinaldo TS, Oliveira AM, Lima RSP et al. Physical Exercise as a Therapeutic Approach in Gastrointestinal Diseases. J Clin Med. 2025;14(5):1708. https://doi.org/10.3390/jcm14051708.

38. Mueller-Lissner S, Kamm MA, Wald A, Hinkel U, Koehler U, Richter E, Bubeck J. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of sodium picosulfate in patients with chronic constipation. Am J Gastroenterol. 2010;105(4):897–903. https://doi.org/10.1038/ajg.2010.41.

39. Rao SSC, Brenner DM. Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review. Am J Gastroenterol. 2021;116(6):1156–1181 https://doi.org/10.14309/ajg.0000000000001222.

40. Luthra P, Camilleri M, Burr NE, Quigley EMM, Black CJ, Ford AC. Efficacy of drugs in chronic idiopathic constipation: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2019;4(11):831–844. https://doi.org/10.1016/S2468-1253(19)30246-8.

41. Whorwell P, Lange R, Scarpignato C. Review article: do stimulant laxatives damage the gut? A critical analysis of current knowledge. Therap Adv Gastroenterol. 2024;17:17562848241249664. https://doi.org/10.1177/17562848241249664.

42. Corsetti M, Landes S, Lange R. Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation. Neurogastroenterol Motil. 2021;33(10):e14123. https://doi.org/10.1111/nmo.14123.

43. Bouchoucha M, Amand C, De Fer BB, Lange R. A Retrospective Real-World Observational Study Assessing the Evolution of Bisacodyl Prescriptions in Patients with Constipation During Long-Term Treatment. Drugs Real World Outcomes. 2023;10(2):249–261. https://doi.org/10.1007/s40801-023-00354-6.

44. Corsetti M, Lacerda A, Patel K, Aran A. Are all stimulant laxatives the same? A comparative perspective on bisacodyl, sodium picosulfate (SPS) and senna. EFSM. 2024;4:240040. Available at: https://www.efsm.online/int_en/article-overview/101/2024/are-all-stimulant-laxatives-the-samea-comparative-perspective-on-bisacodyl-sodium-picosulfate-sps-and-senna.